Cancer Epidemiology Biomarkers & Prevention, Vol 6, Issue 1 21-24, Copyright © 1997 by American Association for Cancer Research

ARTICLES

5 alpha-reductase activity and prostate cancer: a case-control study using stored sera

HA Guess, GD Friedman, MC Sadler, FZ Stanczyk, JH Vogelman, J Imperato-McGinley, RA Lobo and N Orentreich
Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill 27599-7400, USA.

We report a nested case-control study of serum biomarkers of 5 alpha-reductase activity and the incidence of prostate cancer. From a cohort of more than 125,000 members of the Kaiser Permanente Medical Care Program who underwent multiphasic health examinations during 1964-1971, we selected 106 incident prostate cancer cases. A control was pair matched to each case on age, date of serum sampling, and clinic location. Serum levels of total testosterone, free testosterone, androsterone glucuronide, and 5 alpha-androstane-3 alpha,17 beta androstanediol glucuronide (3 alpha-diol G) were measured on the stored samples and scored as quartiles. Potential confounders included alcohol, smoking, and body mass index. The adjusted odds ratios and 95% confidence intervals for a one quartile score increase were 1.00 (0.75-1.34) for total testosterone, 1.14 (0.86-1.50) for free testosterone, 1.13 (0.84-1.53) for androsterone glucuronide, and 1.16 (0.86-1.56) for 3 alpha-diol G. A limitation of this study is that there are two different 5 alpha-reductase isoenzymes, only one of which is expressed in high levels within the prostate, yet both of which may affect serum biomarkers. Since the two isoenzymes are encoded on different chromosomes, variation in one would act as an independent source of measurement error in any analysis of serum biomarker effects of the other. Consequently, the odds ratios may be underestimated and the study, although negative, cannot exclude the previously hypothesized possibility that a positive relationship between intraprostatic 5 alpha-reductase activity and prostate cancer may exist. A clinical trial to test this hypothesis is under way.

This article has been cited by other articles:

				E. Hormones and Prostate Cancer Collaborative Group Endogenous Sex Hormones and Prostate Cancer: A Collaborative Analysis of 18 Prospective Studies J Natl Cancer Inst, February 6, 2008; 100(3): 170 - 183. [Abstract] [Full Text] [PDF]

				I. Boger-Megiddo, N. S. Weiss, M. J. Barnett, G. E. Goodman, and C. Chen V89L Polymorphism of the 5{alpha}-Reductase Type II Gene (SRD5A2), Endogenous Sex Hormones, and Prostate Cancer Risk Cancer Epidemiol. Biomarkers Prev., February 1, 2008; 17(2): 286 - 291. [Abstract] [Full Text] [PDF]

				C. Chen, N. S. Weiss, F. Z. Stanczyk, S. K. Lewis, D. DiTommaso, R. Etzioni, M. J. Barnett, and G. E. Goodman Endogenous Sex Hormones and Prostate Cancer Risk: A Case-Control Study Nested within the Carotene and Retinol Efficacy Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2003; 12(12): 1410 - 1416. [Abstract] [Full Text] [PDF]

				S. Bhasin, A. B. Singh, R. P. Mac, B. Carter, M. I. Lee, and G. R. Cunningham Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan J Androl, May 1, 2003; 24(3): 299 - 311. [Full Text] [PDF]

				B. Cox, M. J. Sneyd, C. Paul, B. Delahunt, and D. C. G. Skegg Vasectomy and Risk of Prostate Cancer JAMA, June 19, 2002; 287(23): 3110 - 3115. [Abstract] [Full Text] [PDF]

				A. P. Chokkalingam, M. Pollak, C.-M. Fillmore, Y.-T. Gao, F. Z. Stanczyk, J. Deng, I. A. Sesterhenn, F. K. Mostofi, T. R. Fears, M. P. Madigan, et al. Insulin-like Growth Factors and Prostate Cancer: A Population-based Case-Control Study in China Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 421 - 427. [Abstract] [Full Text]

				A. H. Wu, A. S. Whittemore, L. N. Kolonel, F. Z. Stanczyk, E. M. John, R. P. Gallagher, and D. W. West Lifestyle Determinants of 5{{alpha}}-Reductase Metabolites in Older African-American, White, and Asian-American Men Cancer Epidemiol. Biomarkers Prev., May 1, 2001; 10(5): 533 - 538. [Abstract] [Full Text]

				M. C. Bosland Chapter 2: The Role of Steroid Hormones in Prostate Carcinogenesis J Natl Cancer Inst Monographs, July 1, 2000; 2000(27): 39 - 66. [Abstract] [Full Text] [PDF]

				T. Shaneyfelt, R. Husein, G. Bubley, and C. S. Mantzoros Hormonal Predictors of Prostate Cancer: A Meta-Analysis J. Clin. Oncol., February 14, 2000; 18(4): 847 - 847. [Abstract] [Full Text] [PDF]

				P. G. Febbo, P. W. Kantoff, E. A. Platz, D. Casey, S. Batter, E. Giovannucci, C. H. Hennekens, and M. J. Stampfer The V89L Polymorphism in the 5{{alpha}}-Reductase Type 2 Gene and Risk of Prostate Cancer Cancer Res., December 1, 1999; 59(23): 5878 - 581. [Abstract] [Full Text] [PDF]

				S. J. Santner, B. Albertson, G.-y. Zhang, G.-h. Zhang, M. Santulli, C. Wang, L. M. Demers, C. Shackleton, and R. J. Santen Comparative Rates of Androgen Production and Metabolism in Caucasian and Chinese Subjects J. Clin. Endocrinol. Metab., June 1, 1998; 83(6): 2104 - 2109. [Abstract] [Full Text]